BioMarin's PKU treatment gets FDA fast-track review

01/30/2006 | PharmaBiz.com (India)

The FDA has granted fast-track review status for BioMarin's Phenoptin for phenylketonuria, an oral small molecule therapeutic currently in phase III development. The company's CEO said the decision reflects the FDA's recognition that PKU "is a serious disease and unmet medical need."

View Full Article in:

PharmaBiz.com (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park